Micardis HCT and Pregnancy -- An Overview
Micardis HCT and Pregnancy Categories C and D
The U.S. Food and Drug Administration (FDA) categorizes Micardis HCT as a pregnancy Category C medicine for the
first trimester and a pregnancy Category D medicine for the second and
third trimesters.
The FDA uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but show side effects to the fetus in animal studies. Pregnancy Category D is given to medicines that have shown clear evidence of risk to the fetus in human studies. It is a stronger warning than for pregnancy Category C medicines. Despite these warnings, a pregnancy Category C or D medicine may still be given to a pregnant woman if her healthcare provider believes that its benefits for the mother outweigh the possible risks to the unborn child.
Micardis HCT and Pregnancy: What Is the Risk?
Some of the complications seen with fetuses or newborns exposed to Micardis HCT during pregnancy include:
- Low blood pressure (hypotension)
- Developmental problems with the nervous system
- Developmental problems with the cardiovascular system (this includes the heart and/or blood vessels)
- Developmental problems with the lungs
- Kidney failure
- Deformities of the head and face
- Jaundice (yellowing of the skin or the whites of the eyes)
- Loss of life.